sur KLEA HOLDING (isin : FR0013481835)
Klea Pharmaceuticals Launches with First Order as It Eyes Growth in Middle East
KLEA HOLDING has announced the commercial launch of its subsidiary, Klea Pharmaceuticals, marking its entry into the Middle East and Africa markets. The company has received its first order from Alphamed in the UAE and is expanding to Bahrain and Qatar. This move is part of Klea Pharmaceuticals' plan to utilise a portfolio of 57 registered medicines.
The company projects a turnover exceeding 8.5 million AED starting from 2026, aiming for growth through geographic expansion to 200 million AED by 2032. It anticipates positive EBITDA from 2026, benefiting Klea Holding's financial results.
To lead this expansion, Klea Pharmaceuticals has appointed Imad Khalfi as Chief Commercial Officer and Abbas Deesawala as Chief Strategy Officer. Their roles include enhancing regulatory strategies and transitioning to an integrated development model in India.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de KLEA HOLDING